Trop-2 expression as a biomarker of response to sacituzumab govitecan in patients with HER2-negative metastatic breast cancer: A pilot study
In this study, Trop-2 expression did not predict excellent response versus non-response to SG in patients with HER2-negative MBC. Low Trop-2 expression, as determined by percentage staining, was predictive of shorter PFS, although the same association was not observed using the H-score. A complete lack of Trop-2 expression may predict SG ineffective, which requires further investigation.
Authors
- Joanne Mortimer (ORCID: https://orcid.org/0000-0002-2935-1934)
- Min Han (ORCID: https://orcid.org/0000-0002-1497-9657)
- Megan Wong (ORCID: https://orcid.org/0000-0003-3799-4400)
- Christina Wei (ORCID: https://orcid.org/0000-0002-3465-6126)
- Nora Ruel (ORCID: https://orcid.org/0000-0002-4591-3618)
- Alexis LeVee (ORCID: https://orcid.org/0000-0001-9821-8144)
- Daniel Schmolze
Institutions
- City of Hope (US)
Publication Details
- Journal
- Cancer Treatment and Research Communications
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1016/j.ctarc.2025.100954
- Citations
- 2
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 2.09
Funders
- National Institutes of Health
- National Cancer Institute